This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY
Top Research Reports for Disney, Novo Nordisk & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).
Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies
by Zacks Equity Research
Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio
by Zacks Equity Research
Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.
Top Stock Reports for Alphabet, Merck & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).
Novo Nordisk Completes Two Studies on Obesity Candidate
by Zacks Equity Research
Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
by Zacks Equity Research
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
3 Diabetes Management Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
by Zacks Equity Research
Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.
Lilly Begins Cardiovascular Outcomes Study on Tirzepatide
by Zacks Equity Research
Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global
Top Stock Reports for Novo Nordisk, IBM & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), International Business Machines (IBM) and Honeywell International (HON).
Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY
by Kinjel Shah
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
Top Analyst Reports for Alibaba, Pfizer & S&P Global
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
NVS vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla